List view / Grid view
Shift Bioscience has published a new study introducing enhanced metrics and baselines for evaluating virtual cell models - boosting gene target discovery and accelerating its rejuvenation therapeutics pipeline.
MitoRx Therapeutics has announced new preclinical data for its small molecule Myo4, showing restored insulin sensitivity and enhanced fat loss with muscle preservation in an obesity model - offering a potential alternative to GLP-1-based therapies.
Using GenAI and expert reasoning, drug developers can now explore an asset’s long-term potential as early as the preclinical stage. This shift is helping to reshape pipeline planning and refine therapeutic strategy.
Japanese researchers have identified the epigenetic enzyme SETD1B as a key driver of aggressive acute myeloid leukaemia (AML) – which could lead to new treatment strategies targeting the cancer’s underlying biology in the future.
Scientists have developed a new AI-guided tool that predicts how bowel cancer becomes resistant to treatment – which could lead to development of new personalised therapies.
As the lab–data science divide continues, Ian Kerman looks ahead to a future of deeper collaboration – one where shared skills, smarter tools and a shift in mindset could finally break down the barriers. In this second interview, he shares his vision, practical ideas and advice for the next generation…
Researchers at POSTECH have developed a new 3D brain model that closely mimics the structure and function of human brain tissue – marking a major advance in early disease detection.
Fauna Bio has launched Fauna Brain™, a powerful new AI platform that leverages the company’s expertise in comparative genomics to accelerate drug target discovery.
How do new cancer drugs make it to patients? This episode uncovers the challenges, successes, and AI advancements driving oncology treatments from preclinical screening to clinical trials.
James Atwood, COO of Opentrons, shares how accessible lab automation is helping research teams tackle tighter budgets, faster timelines and complex discovery workflows.
A practicing surgeon turned biotech CEO is developing a novel pain medicine that could sidestep the failures of both opioids and paracetamol.
A new study at Science Tokyo has developed patient-derived organoids to better understand and combat resistance in oesophageal squamous cell carcinoma (ESCC).
Stanford scientists have successfully grown heart and liver organoids that include functioning blood vessels. This breakthrough overcomes a major size and maturity barrier, which could advance disease modelling and regenerative therapies in the future.
Discover how Domain Therapeutics is using its deep knowledge of GPCR biology to create novel therapeutics with the potential to combat inflammatory diseases such as atopic dermatitis, IBD and arthritis.
Lab scientists and data scientists often speak different languages and that miscommunication can slow down important research. In this interview, Ian Kerman shares how his team is working to break down those walls and spark better collaboration.
